Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease

Summary

Aim: To investigate the efficacy of systemic corticosteroids in treatment for Post-COVID-19 Interstitial Lung Disease. Method: Method: In this multi-centre, prospective, randomised controlled open label clinical trial, patients are divided into two arms: standard treatment arm and standard plus systemic corticosteroid arm. After twelve weeks; clinical, functional, and radiological improvement will being assessed as primary outcomes.

Timeline

Start

2021-05-24

Primary completion

2021-12-31

Completion

2022-01-31

Drugs

Indications